U.S. Industrials Stock News

Earlier this week, Mizuho Securities analyst Joseph Catanzaro initiated coverage on Upstream Bio with a buy rating, signaling fresh Wall Street attention on the biotech name. This coverage launch brings Catanzaro’s recent track record, where fewer than half of his calls were successful but still generated an 8.5% average return, into focus for investors assessing the endorsement’s weight. Next, we’ll examine how this new Mizuho coverage and Catanzaro’s track record might influence Upstream...

DNOW (DNOW) just landed on more investors' radar after Texas Capital’s Matthew Key initiated coverage, highlighting the company’s combined scale with MRC Global and the potential cash flow boost from cost synergies and cross selling. See our latest analysis for DNOW. That call out comes on the back of a $13.69 share price that has delivered a solid 8.82 percent 1 month share price return and an impressive 5 year total shareholder return of almost 100 percent. This suggests long term momentum...

In recent days, Susquehanna initiated coverage of Fabrinet with a Positive rating while investors focused on its role packaging and testing photonic modules that underpin AI data centers and advanced optical networking. This attention underscores how Fabrinet’s specialized photonic capabilities and expanding presence in AI server manufacturing are increasingly viewed as central to the AI hardware supply chain. We’ll now explore how this growing recognition of Fabrinet’s role in AI data...

Artivion (AORT) climbed about 5% after positive analyst commentary related to its On-X mechanical heart valve, with new clinical studies indicating a potentially larger U.S. market and stronger demand among younger patients. See our latest analysis for Artivion. The latest enthusiasm around On-X comes on top of a strong run, with Artivion's share price up sharply this year and a three year total shareholder return of nearly 300 percent signaling sustained momentum rather than a one off...

Eastern Bankshares (EBC) has quietly outperformed many regional peers, with the stock up about 12% over the past year and roughly 21% across the past 3 years, despite some recent weekly weakness. See our latest analysis for Eastern Bankshares. Despite a recent 1 week share price pullback, Eastern Bankshares still shows constructive momentum, with a roughly 8 percent 1 month share price return and solid double digit multi year total shareholder returns suggesting confidence in its growth and...

NuScale Power Corporation disclosed that shareholders at a special meeting on December 16, 2025 approved an amendment to its Certificate of Incorporation, raising the authorized Class A common shares from 332,000,000 to 662,000,000 to support future financing and corporate needs. This shift nearly doubles NuScale’s potential equity issuance capacity, sharpening investor attention on how the company balances funding its capital‑intensive small modular reactor ambitions against dilution risk...

H World Group (NasdaqGS:HTHT) has quietly been rewarding patient shareholders, with the stock up about 51% year to date and roughly 27% over the past 3 months, outpacing many consumer-facing peers. See our latest analysis for H World Group. With the share price now around $49.12 and a robust 30 day share price return of 11.43%, H World’s recent momentum builds on an already strong year to date and solid multi year total shareholder returns. If H World’s steady climb has caught your eye, this...

In December 2025, Centuri Holdings, Inc. announced it had secured nearly US$500 million in new customer awards and renewals across its core electric and gas infrastructure services, lifting year-to-date bookings to about US$4.30 billion. The mix of mostly new work, spanning large natural gas distribution, pipeline replacement, and substation upgrade projects in the U.S. and Canada, underscores Centuri’s role in supporting essential energy and telecom infrastructure. Next, we’ll examine how...

In December 2025, Wedbush highlighted Tyra Biosciences’ advancing clinical pipeline, pointing to upcoming Phase 2 data in 2026 and a planned Phase 2 trial in upper tract urothelial carcinoma, while the company refreshed its leadership with new chief operating and regulatory officers. The combination of maturing late-stage programs and strengthened executive oversight underscores how Tyra is positioning itself to potentially move targeted therapies to market more efficiently. We’ll now...

Earlier in December, Stifel Financial reported selected operating results for November 2025, highlighting record total client assets and fee-based client assets, which rose 8% and 14% year over year on the back of strong adviser recruiting and market gains. Management also pointed to elevated Institutional Group client activity and voiced confidence in a strong fourth quarter despite the government shutdown, underscoring how Stifel’s recruitment push is translating into higher client...

Vishay Precision Group, Inc. ( NYSE:VPG ) shareholders would be excited to see that the share price has had a great...

PennyMac Financial Services, a U.S. mortgage finance company, recently reported Q3 2025 results that exceeded analyst expectations for earnings per share and revenue, while its subsidiary PennyMac Corp. priced US$75,000,000 of 8.500% exchangeable senior notes due 2029 to refinance existing debt and support general corporate needs. At the same time, fresh analyst coverage highlighting potential for steadier earnings alongside a backdrop of easing inflation and Treasury yields has improved...

Piper Sandler previously initiated coverage on WesBanco (WSBC) with an Overweight rating, basing its view on expectations for lower short-term Federal Reserve rates, a modestly steeper yield curve, and a solid economic backdrop for bank credit and growth. This renewed analyst attention on WesBanco’s interest-rate sensitivity and earnings outlook has sharpened investor focus on how its business mix might respond to a changing rate cycle. We’ll now examine how Piper Sandler’s emphasis on...

AnaptysBio (ANAB) has quietly turned into a strong momentum story, with the stock up about 3% on the day, roughly 9% over the past week, and more than 30% this month. See our latest analysis for AnaptysBio. Zooming out, that sharp 1 day and 30 day share price momentum sits on top of a powerful year to date share price return, while the 1 year total shareholder return shows that optimism has been building for some time. If AnaptysBio's surge has you rethinking your exposure to biotech, it...

In recent weeks, Luckin Coffee reported double-digit growth in store count, monthly active customers, same-store sales, and revenue, while also confirming it is in early-stage talks to acquire premium brands such as Nestlé’s Blue Bottle Coffee and the operator of % Arabica’s China business. This combination of rapid operational expansion and a potential move upmarket into premium coffee suggests Luckin is testing how far its model can stretch beyond low-priced, app-driven beverages. With...

To the annoyance of some shareholders, Vivid Seats Inc. ( NASDAQ:SEAT ) shares are down a considerable 25% in the last...

Array Technologies, Inc. ( NASDAQ:ARRY ) shareholders would be excited to see that the share price has had a great...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Even if it's not a huge purchase, we think it was good to see that David Lorber, the Chairman & CEO of PhenixFIN...

Key Insights Leishen Energy Holding's estimated fair value is US$4.50 based on 2 Stage Free Cash Flow to Equity Current...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

QXO, Inc. ( NYSE:QXO ) shares have had a really impressive month, gaining 34% after a shaky period beforehand. The last...

Limoneira Company's ( NASDAQ:LMNR ) investors are due to receive a payment of $0.075 per share on 16th of January. The...